Headquarters: Paris, France
Year Established: 2004
Revenues: $35,633 (-1%)
Net Income: $9,782 (flat)
R&D: $5,449 (+2%)
TOP SELLING DRUGS
|Plavix||heart attack, stroke||$1,627||-20%|
Sanofi reported revenues of $35.6 billion for 2016, dropping it from number three last year ($40.4B) to number 6 this year, due mostly to the negative impact of foreign exchange rates. The year started with Paris-based Sanofi reorganizing its business, which now consists of the following five business units: Sanofi Genzyme, the specialty care business that includes multiple sclerosis, rare diseases, and oncology; Diabetes and Cardiovascular; Generic Medicines and Emerging Markets; Consumer Healthcare; and Sanofi Pasteur, or the Human Vaccines segment. On January 1, 2017, Sanofi and Boehringer Ingelheim completed the exchange of Merial, Sanofi’s animal health business and Boehringer Ingelheim’s consumer healthcare business.
Strengthening biologics footprint
Sanofi grew its biologics footprint during the year through research collaborations and facility expansions. With Global Genomics Group (G3) it entered into a research collaboration to identify new signaling pathways and targets involved in coronary artery disease. The companies will use G3’s platform with data from its G3LOBAL Database to further decipher the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with these signaling pathways.
In a deal with Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., Sanofi Deutschland GmbH, entered a strategic alliance to discover and develop small molecule inhibitors for multiple targets in metabolic disorders. The research alliance aims to develop therapeutic small molecules that will address the unmet needs in diabetes and obesity. Jubilant will provide drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism. The research for the projects take place at R&D labs of Jubilant Biosys and Jubilant Chemsys in Noida, India.
Sanofi and Innate Pharma entered a research collaboration and licensing agreement to apply Innate Pharma’s new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the activating receptor NKp46. Both companies will work together on the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi’s proprietary bispecific antibody format as well as tumor targets. Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to receive as much as $450 million in development and commercial milestone payments, as well as royalties on net sales.
Recursion Pharmaceuticals entered a research agreement with Sanofi Genzyme to deploy its drug repurposing platform to identify new uses for Sanofi’s clinical stage molecules across dozens of genetic diseases. Recursion generates human cellular models of many diseases and uses computer vision to extract thousands of morphological measures at the level of individual cells. Molecules are then screened for their ability to rescue phenotypic defects associated with each disease. Recursion has already used the platform to generate an internal pipeline of candidates for a handful of genetic diseases, with a lead asset nearing IND for the treatment of Cerebral Cavernous Malformation. Sanofi will provide Recursion with a number of small molecules, and Recursion will screen these molecules across its extensive and rapidly expanding library of genetic disease models. Sanofi Genzyme will have the option to develop products targeting any new indications identified.
Warp Drive Bio, a life sciences company developing therapeutics that exploit the molecules and mechanisms of nature, during the year reached a milestone in the antibiotic discovery program under its research collaboration with Sanofi. Sanofi assumed all preclinical and clinical development efforts for the novel aminoglycoside antibiotic candidates discovered by Warp Drive. This program is one of several natural product-based programs utilizing Warp Dive’s Genome Mining technology platform.
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S.
Department of Health and Human Services, awarded Sanofi a $37.6 million contract to supply and manage inventory for Leukine. Sanofi Genzyme is developing Leukine for the treatment of acute radiation syndrome, a serious illness that occurs in people exposed to high doses of radiation. In 2013, Sanofi was awarded a $36.5 million contract for late stage development and procurement of Leukine. Since then Sanofi Genzyme has conducted studies regarding the potential use of Leukine in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome). The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA this year.
Sanofi also unveiled plans to develop and commercialize biologics in China through a partnership with JHL Biotech, a biopharma company with development and manufacturing facilities in Wuhan and Taiwan. The two companies entered a strategic alliance to develop and commercialize biologics in China with potential international expansion.
As part of the deal, Sanofi invested $80 million in newly issued JHL shares and paid $21 million upfront to acquire exclusive rights for the proposed biosimilar of Rituximab and options to certain JHL pipeline products. JHL will lead the development, registration, and manufacturing activities, while Sanofi will lead commercialization efforts in China. JHL is entitled to receive milestones of as much as $236 million and sales royalties.